Commercial Coverage For Specialty Drugs Lacks Consistency, Study Finds
Executive Summary
Coverage decisions are also often more restrictive than drug labeling, according to researchers from Tufts.
You may also be interested in...
Orphan Drug Access: One-Third Of US Coverage Decisions Involve Restrictions, Study Finds
Tufts researchers report restrictions are more common for orphan drugs indicated for diseases with higher prevalence and that are more expensive.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.